Homeobox (HOX) genes are members of a transcription factor family and play a crucial role in embryonic development and in the control of differentiation of adult hematopoietic cells [1, 2] . DNA methylation in the 5′ region of the genes, particularly of the CpG islands, has been clearly linked to the repression of gene transcription and is known to play an important role in tumor development [3, 4] . Concerning hematologic malignancies, recent studies have shown that hypermethylation of the HOXA4 gene is associated with transcriptional repression in chronic lymphocytic leukemia and that extremely high methylation levels of HOXA5 are observed in AML, far greater than that seen in normal hematopoietic cells [5, 6] . The HOXA genes are associated not only with the development of hematologic malignancies but also with the prognosis of these conditions. The inactivation of HOXA4 and HOXA5 genes by hypermethylation is strongly correlated with progression to blast crisis in CML [6] , and some recent studies have shown that increased expression of HOXA genes is correlated to the cytogenetic findings associated with poor prognosis in AML and mixed lineage leukemia [7, 8] . Nevertheless, the clear-cut correlation of HOXA5 with prognosis in AML has not been reported. In this study, we quantified the level of HOXA5 methylation by pyrosequencing and examined its correlation with the clinical outcome. We 469 � Brief Communication•Diagnostic Hematology �
Hypermethylation of the homeobox (HOX) gene promoter leads to decreased expression of the gene during tumor development and is thought to be correlated with the clinical outcome in leukemia. In this study, we performed pyrosequencing to quantify the methylation level of HOXA5 genes in the bone marrow samples obtained from 50 patients with AML and 19 normal controls. The methylation percentage of HOXA5 in AML patients (median=65.4%, interquartile range=35.9-72.3%) was higher than that of HOXA5 in control patients (median=43.1%, interquartile range=36.7-49.6%, Mann-Whitney U test, P=0.012). The patients of the AML group who had a high methylation percentage (>70%) had a good prognosis with a 3-yr overall survival (OS) of 82.5%, whereas the patients with a low methylation percentage (≤70%) showed a 3-yr OS of 40.5% (P=0.048). Cox proportional hazards regression showed that the methylation percentages of HOXA5 were independently associated with the 3-yr OS of AML patients, regardless of their karyotypes. We propose that the quantification of HOXA5 methylation by pyrosequencing may be useful for predicting short-term prognosis in AML. However, the limitations of our study are the small sample size and its preliminary nature. Thus, a larger study should be performed to clearly determine the relationships among HOXA5 methylation levels, cytogenetics, and prognosis in AML patients. The 50 AML patients showed significantly higher percentages of methylation (Mann-Whitney U test, P=0.012) (median=65.4%, interquartile range=35.9-72.3%) than the 19 healthy control individuals (median=43.1%, interquartile range=36.7-49.6%). The ROC curve analysis showed that a cut-off of 70% HOXA5 methylation yielded sensitivity and specificity of 60% and 100%, respectively ( Fig   1) . We divided the AML patients into 2 subgroups on the basis of the 70% cut-off for HOXA5 methylation derived from the ROC curve analysis. The patients whose HOXA5 methylation percentage was greater than 70% showed more favorable karyotypes at the time of diagnosis than those whose HOXA5 methylation percentage was less than 70% ( Table 1 ). The other clinical variables were not ROC curve analysis showed that a cut-off of 70% HOXA5 methylation yielded sensitivity and specificity of 60% and 100%, respectively. statistically significant.
Among AML patients, the patients with high HOXA5 methylation percentage (>70%) showed a better 3-yr overall survival than those with low methylation percentage (HOXA5 methylation percentage ≤70%) (82.5%
vs. 40.5%, respectively, P=0.048, Fig. 2 ). Multivariate Cox proportional hazards regression showed that HOXA5 methylation was an independent factor associated with the 3-yr overall survival of AML patients and with the karyotypic findings of the leukemic cells ( Table 2 ).
In this study, the level of HOXA5 methylation showed significant association with short-term mortality in AML patients. Interestingly, HOXA5 methylation showed cor- [10] . Even though in this study, the proportion of favorable AML karyotypes was greater in patients showing high methylation percentage (>70%) than in those with low methylation percentage (≤70%), hypermethylation proved to be an independent factor for the overall survival. There have been conflicting data on the prognostic impact of HOXA5 methylation. One study showed that hypermethylation of both HOXA5 and HOXA4
was strongly correlated with progression to blast crisis in CML and that hypermethylation was more strongly correlated to normal karyotype than favorable karyotype in AML patients [6] . However, Strathdee et al. [10] also reported that hypermethylation was observed in all cytogenetic-risk groups. Recently, several researches consistently reported that low HOX expression levels were correlated with favorable AML. Andreeff et al. [13] showed that downregulated HOX expression was a consistent feature in favorable AML patients. Debernardi et al. [14] showed similar results in their study. Since gene methylation downregulates its expression, low HOXA5 expression in favorable AML would be directly related to hypermethylation of HOXA5. In our study, HOXA5 was hypermethylated in the favorable group rather than in the intermediate or unfavorable groups. Our results indicate that hypermethylation shows a good correlation with prognosis in AML patients, thereby corroborating the findings of Andreeff et al. [13] . Other HOX genes (HOXA7-11 genes) are "upregulated together"in AML, and their increased expression is also correlated with poor prognosis in AML [15] . Because there is no surrogate marker other than cytogenetic classification for prognosis of AML patients, HOX gene methylation can be considered as a surrogate predictor of survival or response to therapy.
In conclusion, the quantification of HOXA5 methylation level by pyrosequencing was found to be useful for predicting short-term prognosis in AML patients. This finding indicates that downregulation of HOXA5 by methylation could be related to favorable AML. However, the small sample size and the preliminary nature of this study are the limitations of our study. Thus, a larger study should be performed to clearly determine the relationships among HOXA5 methylation levels, cytogenetics, and prognosis of AML patients.
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